Splice variants of the forkhead box protein AFX exhibit dominant negative activity and inhibit AFXα-mediated tumor cell apoptosis

Eun Jig Lee, Jeong Mo Kim, Mi Kyung Lee, J. Larry Jameson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Loss-of-function in the apoptosis-inducing genes is known to facilitate tumorigenesis. AFX (FOXO4), a member of forkhead transcription factors functions as a tumor suppressor and has 2 isoforms, AFXα (505 a.a.) and AFXζ (450 a.a.). In human cancer cells, we identified an N-terminally deleted form of AFXα (α198-505), translated from a downstream start and 2 short N-terminal AFX proteins (90, and 101 a.a.) produced by aberrant splicing. Methods and Findings: We investigated the expression and role of these AFX variants. Cell transduction study revealed that short N-terminal AFX proteins were not stable. Though α(198-505) protein expression was detected in the cytoplasm and nucleus, α(198-505) expressing cells did not show a nucleocytoplasmic shuttling mediated by PI3 kinase signaling. Whereas, we observed this shuttling in cells expressing, either AFXα or AFXζ protein. AFXζ and α(198-505) lost the ability to transactivate BCL6 or suppress cyclin D2 gene expression. These variants did not induce cancer cell death whereas AFXα resulted in apoptosis. We found that AFXζ and α(198-505) suppress the AFXα stimulation of BCL6 promoter in a dose dependent manner, indicating dominant negative activity. These variants also inhibited AFXα induction of apoptosis. Conclusions: Loss of function by aberrant splicing and the dominant negative activity of AFX variants may provide a mechanism for enhanced survival of neoplastic cells.

Original languageEnglish
Article numbere2743
JournalPloS one
Volume3
Issue number7
DOIs
Publication statusPublished - 2008 Jul 23

Fingerprint

Forkhead Transcription Factors
Tumors
apoptosis
Cells
Apoptosis
Neoplasms
Proteins
proteins
Cyclin D2
cyclins
cells
carcinogenesis
cell death
phosphotransferases (kinases)
Cell death
cytoplasm
transcription factors
protein synthesis
Phosphatidylinositol 3-Kinases
promoter regions

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

@article{dce057b68cbe41beaee780e0859097e0,
title = "Splice variants of the forkhead box protein AFX exhibit dominant negative activity and inhibit AFXα-mediated tumor cell apoptosis",
abstract = "Background: Loss-of-function in the apoptosis-inducing genes is known to facilitate tumorigenesis. AFX (FOXO4), a member of forkhead transcription factors functions as a tumor suppressor and has 2 isoforms, AFXα (505 a.a.) and AFXζ (450 a.a.). In human cancer cells, we identified an N-terminally deleted form of AFXα (α198-505), translated from a downstream start and 2 short N-terminal AFX proteins (90, and 101 a.a.) produced by aberrant splicing. Methods and Findings: We investigated the expression and role of these AFX variants. Cell transduction study revealed that short N-terminal AFX proteins were not stable. Though α(198-505) protein expression was detected in the cytoplasm and nucleus, α(198-505) expressing cells did not show a nucleocytoplasmic shuttling mediated by PI3 kinase signaling. Whereas, we observed this shuttling in cells expressing, either AFXα or AFXζ protein. AFXζ and α(198-505) lost the ability to transactivate BCL6 or suppress cyclin D2 gene expression. These variants did not induce cancer cell death whereas AFXα resulted in apoptosis. We found that AFXζ and α(198-505) suppress the AFXα stimulation of BCL6 promoter in a dose dependent manner, indicating dominant negative activity. These variants also inhibited AFXα induction of apoptosis. Conclusions: Loss of function by aberrant splicing and the dominant negative activity of AFX variants may provide a mechanism for enhanced survival of neoplastic cells.",
author = "Lee, {Eun Jig} and Kim, {Jeong Mo} and Lee, {Mi Kyung} and Jameson, {J. Larry}",
year = "2008",
month = "7",
day = "23",
doi = "10.1371/journal.pone.0002743",
language = "English",
volume = "3",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

Splice variants of the forkhead box protein AFX exhibit dominant negative activity and inhibit AFXα-mediated tumor cell apoptosis. / Lee, Eun Jig; Kim, Jeong Mo; Lee, Mi Kyung; Jameson, J. Larry.

In: PloS one, Vol. 3, No. 7, e2743, 23.07.2008.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Splice variants of the forkhead box protein AFX exhibit dominant negative activity and inhibit AFXα-mediated tumor cell apoptosis

AU - Lee, Eun Jig

AU - Kim, Jeong Mo

AU - Lee, Mi Kyung

AU - Jameson, J. Larry

PY - 2008/7/23

Y1 - 2008/7/23

N2 - Background: Loss-of-function in the apoptosis-inducing genes is known to facilitate tumorigenesis. AFX (FOXO4), a member of forkhead transcription factors functions as a tumor suppressor and has 2 isoforms, AFXα (505 a.a.) and AFXζ (450 a.a.). In human cancer cells, we identified an N-terminally deleted form of AFXα (α198-505), translated from a downstream start and 2 short N-terminal AFX proteins (90, and 101 a.a.) produced by aberrant splicing. Methods and Findings: We investigated the expression and role of these AFX variants. Cell transduction study revealed that short N-terminal AFX proteins were not stable. Though α(198-505) protein expression was detected in the cytoplasm and nucleus, α(198-505) expressing cells did not show a nucleocytoplasmic shuttling mediated by PI3 kinase signaling. Whereas, we observed this shuttling in cells expressing, either AFXα or AFXζ protein. AFXζ and α(198-505) lost the ability to transactivate BCL6 or suppress cyclin D2 gene expression. These variants did not induce cancer cell death whereas AFXα resulted in apoptosis. We found that AFXζ and α(198-505) suppress the AFXα stimulation of BCL6 promoter in a dose dependent manner, indicating dominant negative activity. These variants also inhibited AFXα induction of apoptosis. Conclusions: Loss of function by aberrant splicing and the dominant negative activity of AFX variants may provide a mechanism for enhanced survival of neoplastic cells.

AB - Background: Loss-of-function in the apoptosis-inducing genes is known to facilitate tumorigenesis. AFX (FOXO4), a member of forkhead transcription factors functions as a tumor suppressor and has 2 isoforms, AFXα (505 a.a.) and AFXζ (450 a.a.). In human cancer cells, we identified an N-terminally deleted form of AFXα (α198-505), translated from a downstream start and 2 short N-terminal AFX proteins (90, and 101 a.a.) produced by aberrant splicing. Methods and Findings: We investigated the expression and role of these AFX variants. Cell transduction study revealed that short N-terminal AFX proteins were not stable. Though α(198-505) protein expression was detected in the cytoplasm and nucleus, α(198-505) expressing cells did not show a nucleocytoplasmic shuttling mediated by PI3 kinase signaling. Whereas, we observed this shuttling in cells expressing, either AFXα or AFXζ protein. AFXζ and α(198-505) lost the ability to transactivate BCL6 or suppress cyclin D2 gene expression. These variants did not induce cancer cell death whereas AFXα resulted in apoptosis. We found that AFXζ and α(198-505) suppress the AFXα stimulation of BCL6 promoter in a dose dependent manner, indicating dominant negative activity. These variants also inhibited AFXα induction of apoptosis. Conclusions: Loss of function by aberrant splicing and the dominant negative activity of AFX variants may provide a mechanism for enhanced survival of neoplastic cells.

UR - http://www.scopus.com/inward/record.url?scp=50549100170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549100170&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0002743

DO - 10.1371/journal.pone.0002743

M3 - Article

C2 - 18648506

AN - SCOPUS:50549100170

VL - 3

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e2743

ER -